Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Annovis Bio, Inc.
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
October 24, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
July 18, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces the Filing of a Groundbreaking Patent
June 27, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
June 20, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.